BridgeMD
Tests treatment safety and results for Acute Decompensated Heart Failure
Official title Efficacy and Safety of Combination Diuretic Therapy in Patients With Acute Decompensated Heart Failure and Volume Overload
ClinicalTrials.gov ID: NCT06414759
What this study is testing
What is Acetazolamide?
Acetazolamide is an investigational medicine, given as an once-daily pill taken by mouth, being studied as a potential treatment for acute decompensated heart failure.
Also referred to as Carbonic anhydrase inhibitor.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study aims to compare two medications, acetazolamide and metolazone, along with loop diuretics, to see which one works better and is safer for patients with ADHF who have volume overload. By comparing these medications, we hope to learn which one can help these patients the most.
- Phase 4: studies an already-approved treatment
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65
You may be able to join if
- Male or female patients with ages ≥ 18 years old, and less than 65 years old.
- For both elective and emergency hospital admissions, patients with a clinical diagnosis of ADHF must exhibit at least one clinical sign indicative of...
You likely can't join if
- Patient diagnosed with acute kidney injury upon hospital admission based on the presence of any of the following criteria: an increase in SCr by at...
- Patients with acute pulmonary edema caused by increased afterload and fluid redistribution to the lungs in the absence or with minimal fluid...
- Anticipated exposure to nephrotoxic agents (such as contrast dye) during hospitalization.
- Patients who exhibit anuria or are undergoing renal replacement therapy or ultrafiltration.
- Patients with eGFR less than 30 mL/min/1.73m² at the time of screening.
- Expected use of intravenous inotropes, vasopressors, or nitroprusside during the study.
See the full eligibility criteria
- Male or female patients with ages ≥ 18 years old, and less than 65 years old.
- For both elective and emergency hospital admissions, patients with a clinical diagnosis of ADHF must exhibit at least one clinical sign indicative of volume overload. These signs may include edema (score 2 or higher)...
- Patient diagnosed with acute kidney injury upon hospital admission based on the presence of any of the following criteria: an increase in SCr by at least 0.3 mg/dL within 48 hours, an increase in SCr to at least 2 times...
- Patients with acute pulmonary edema caused by increased afterload and fluid redistribution to the lungs in the absence or with minimal fluid accumulation.
- Anticipated exposure to nephrotoxic agents (such as contrast dye) during hospitalization.
- Patients who exhibit anuria or are undergoing renal replacement therapy or ultrafiltration.
- Patients with eGFR less than 30 mL/min/1.73m² at the time of screening.
- Expected use of intravenous inotropes, vasopressors, or nitroprusside during the study.
- Prior cardiac transplantation and/or utilization of a ventricular assist device.
- Blood pressure below 90 mmHg or mean arterial pressure below 65 mmHg at the time of recruitment.
- Patients who are pregnant or breastfeeding.
- Administration of acetazolamide or metolazone within the one-month period preceding randomization.
- The usage of any diuretic agent during the treatment phase is not specified in the study protocol, except for mineralocorticoid receptor antagonists.
The study team makes the final eligibility decision.
Where it's taking place
- Giza, GZ, Egypt
Compensation & support
A stipend or compensation may be offered.
Compensation likely.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Giza, GZ, Egypt. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.